Columbia Partners L L C Investment Management purchased a new stake in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 112,538 shares of the company’s stock, valued at approximately $1,257,000. Columbia Partners L L C Investment Management owned 0.05% of Endo International PLC as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Sivik Global Healthcare LLC bought a new position in Endo International PLC during the second quarter valued at about $2,793,000. Amalgamated Bank grew its position in Endo International PLC by 34.0% during the second quarter. Amalgamated Bank now owns 43,348 shares of the company’s stock valued at $484,000 after buying an additional 10,991 shares during the period. Nationwide Fund Advisors grew its position in Endo International PLC by 4.9% during the second quarter. Nationwide Fund Advisors now owns 360,787 shares of the company’s stock valued at $4,030,000 after buying an additional 16,913 shares during the period. Ameriprise Financial Inc. grew its position in Endo International PLC by 4.9% during the second quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock valued at $6,497,000 after buying an additional 27,414 shares during the period. Finally, Icon Advisers Inc. Co. grew its position in Endo International PLC by 61.1% during the second quarter. Icon Advisers Inc. Co. now owns 120,172 shares of the company’s stock valued at $1,342,000 after buying an additional 45,572 shares during the period. Institutional investors own 90.71% of the company’s stock.

Shares of Endo International PLC (ENDP) traded up 0.95% during midday trading on Wednesday, hitting $8.47. 228,927 shares of the stock were exchanged. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $23.98. The firm’s 50 day moving average price is $8.73 and its 200-day moving average price is $10.80. The stock’s market cap is $1.89 billion.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.86 EPS. On average, equities research analysts expect that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Columbia Partners L L C Investment Management Takes Position in Endo International PLC (ENDP)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/20/columbia-partners-l-l-c-investment-management-takes-position-in-endo-international-plc-endp.html.

In related news, CEO Paul Campanelli acquired 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the purchase, the chief executive officer now owns 213,620 shares in the company, valued at approximately $1,647,010.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Terrance J. Coughlin acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, with a total value of $154,000.00. Following the completion of the purchase, the chief operating officer now owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 36,000 shares of company stock valued at $279,460. 0.50% of the stock is currently owned by corporate insiders.

Several equities analysts recently weighed in on the stock. Stifel Nicolaus lowered shares of Endo International PLC from a “buy” rating to a “hold” rating and reduced their price target for the company from $22.00 to $15.00 in a research report on Friday, June 9th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Canaccord Genuity set a $12.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research report on Thursday, June 8th. ValuEngine lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Mizuho restated a “buy” rating and set a $19.00 price target (up previously from $18.00) on shares of Endo International PLC in a research report on Thursday, May 25th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $14.33.

Endo International PLC Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Institutional Ownership by Quarter for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.